pharmaceutical portfolio management

By Michelle Vitko,Research Analyst The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a...

By Ryan McGuire,Senior Research Analyst This is the third installment in a blog series focusing on counter-generic strategies. You can read part 1 about the patent cliff and the second part on patent litigation. Under the FDA's Modernization Act Continue...

By Jeremy Spivey,Senior Research Analyst Preliminary survey results from our ongoing portfolio management study have already revealed some interesting details. Among them: * Government payer reimbursement rates for products are Continue reading “Portfolio...

This is the first entry in a series that will focus on countering generic competition and preserving pharmaceutical brand revenue. Much has been made about the slew of drugs that face the loss of patent protection in 2011. In all, experts estimate that $30...

Key Finding #4 from our Counter-Generics and Biosimilar Threats research: Short-term strategies are still the most popular, but line-extension tactics gaining favor. Over the past three years, short-term strategies, including litigation and defensive pricing,...

The Biologics Price Competition and Innovation Act (BPCI), passed by Congress in 2009, was intended by its sponsors to reign in the rising healthcare cost. Two years later the FDA still has not established complete guidance on an abbreviated pathway for biosimilars...

Counter-generics tactics will evolve, but not radically change, between now and 2014, according to our latest portfolio management research. There are some favored tactics that companies plan to use more frequently going forward than they have up until now. As...

New data show that 54% of drug companies sign in-licensing deals to accelerate development timelines. Our new study, “Pharmaceutical Business Development and Licensing: Strengthening Pipelines and Managing Relationships,” examines drug companies’ strategies...

Partners that understand each other's goals cultivate a healthier partnership, whether their focus is on revenue or expanding capabilities. When evaluating a deal’s potential profitability, pharmaceutical and biotechnology business development and licensing...

Brand Teams Protect Their Products with an Average of Five Distinct Strategies Successful pharmaceutical and biotechnology product teams are finding that spreading their bets across multiple strategies produces the best results, according to a new report on...